Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
FASEB J ; 3(8): 1968-71, 1989 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2721857

RESUMEN

Adoptively transferred allergic encephalomyelitis can be inhibited by various phosphosugars, particularly mannose-6-phosphate. The sugar specificity suggests that inhibition may be due to depletion of lymphocyte cell-surface lysosomal enzymes, which are essential for the passage of lymphocytes across the vascular endothelium and the entry of lymphocytes into the central nervous system parenchyma.


Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Hexosafosfatos/uso terapéutico , Manosafosfatos/uso terapéutico , Animales , Enfermedades Autoinmunes/inmunología , Relación Dosis-Respuesta a Droga , Encefalomielitis Autoinmune Experimental/inmunología , Femenino , Inmunidad Celular , Linfocitos/enzimología , Linfocitos/inmunología , Masculino , Manosafosfatos/administración & dosificación , Ratas
2.
Kardiologiia ; 20(5): 80-4, 1980 May.
Artículo en Ruso | MEDLINE | ID: mdl-7392389

RESUMEN

It was established in experiments on 24 dogs with ligated interventricular branch of the left coronary artery that hexosophosphate (0.5 and 1 ml/kg intravenously) increases the collateral coronary blood flow and myocardial contractility against the background of a decrease in the lactate content in blood draining from the ischemic zone. Preliminary injection of hexosophosphate to rabbits increases the respiratory control in mitochondria from the ischemic myocardium. Drip intravenous hexosophosphate (100 ml) infusion to patients in the acute period of myocardial infarction reduced significantly sigma ST in precardiac leads and reduced the lactic acid content in venous blood. In 7.6% of cases hexosophosphate caused arrest or abatement of the pain syndrome.


Asunto(s)
Enfermedad Coronaria/tratamiento farmacológico , Metabolismo Energético/efectos de los fármacos , Hexosafosfatos/uso terapéutico , Enfermedad Aguda , Anciano , Animales , Circulación Colateral/efectos de los fármacos , Perros , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Femenino , Corazón/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/tratamiento farmacológico , Miocardio/metabolismo , Conejos , Factores de Tiempo
3.
Vestn Khir Im I I Grek ; 118(2): 77-81, 1977 Feb.
Artículo en Ruso | MEDLINE | ID: mdl-324108

RESUMEN

The authors' experience with the clinical use of an antihypoxic substnace--hexosophosphate representing the complex of tetraphosphoric glucose and fructose esters is reported. The substance was studied experimentally on 20 dogs and clinically in 126 patients with diseases of vessels, abdominal organs and the kidneys. A positive effect was gained in peroral and intravenous use of the substance both with theaim of preparative management of patients to be subjected to major surgery and postoperatively. HP, being a readily absorbed energetic substance, renders a normalizing effect on the hemodynamics, the bowel activity, improves general patients'state, that is of special value in patients whose state is aggravated by concomitant lesions.


Asunto(s)
Hexosafosfatos/uso terapéutico , Procedimientos Quirúrgicos Operativos , Adulto , Animales , Ensayos Clínicos como Asunto , Perros , Evaluación de Medicamentos , Hexosafosfatos/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Cuidados Posoperatorios , Cuidados Preoperatorios , Choque/tratamiento farmacológico , Choque/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...